Atopic Dermatitis

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.

CLEVELAND — For patients with atopic dermatitis, today’s systemic therapies can lead to long-standing on-drug relief, but long-term, off-drug remission remains a goal that has yet to be reached, according to Raj Chovatiya, MD, PhD.

Dermatologist Raj Chovatiya, MD, PhD, MSCI, recently spoke to Healio about his new findings in seborrheic dermatitis and how to best treat diverse patient groups with this condition.

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

Due to a small increase in eczematous dermatitis, older adults taking antihypertensive drugs should be monitored and this possibility considered when assessing for eczema, according to a study.

Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Young infants with lower lung function and impaired skin barrier function experienced greater risks for developing asthma by age 3 years, according to a study published in Allergy.

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release.